[go: up one dir, main page]

FI964593L - Oraalisia nestemäisiä alendronaattikokoonpanoja - Google Patents

Oraalisia nestemäisiä alendronaattikokoonpanoja Download PDF

Info

Publication number
FI964593L
FI964593L FI964593A FI964593A FI964593L FI 964593 L FI964593 L FI 964593L FI 964593 A FI964593 A FI 964593A FI 964593 A FI964593 A FI 964593A FI 964593 L FI964593 L FI 964593L
Authority
FI
Finland
Prior art keywords
oral liquid
alendronate formulations
formulations
liquid alendronate
oral
Prior art date
Application number
FI964593A
Other languages
English (en)
Swedish (sv)
Other versions
FI964593A0 (fi
FI118296B (fi
Inventor
Gerald S Brenner
Ashok V Katdare
Denise Pretzer
Donna T Whiteford
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of FI964593A0 publication Critical patent/FI964593A0/fi
Publication of FI964593L publication Critical patent/FI964593L/fi
Application granted granted Critical
Publication of FI118296B publication Critical patent/FI118296B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI964593A 1994-05-17 1996-11-15 Oraalisia nestemäisiä alendronaattikokoonpanoja FI118296B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/245,289 US5462932A (en) 1994-05-17 1994-05-17 Oral liquid alendronate formulations
US24528994 1994-05-17
PCT/US1995/005926 WO1995031203A1 (en) 1994-05-17 1995-05-12 Oral liquid alendronate formulations
US9505926 1995-05-12

Publications (3)

Publication Number Publication Date
FI964593A0 FI964593A0 (fi) 1996-11-15
FI964593L true FI964593L (fi) 1996-11-15
FI118296B FI118296B (fi) 2007-09-28

Family

ID=22926074

Family Applications (1)

Application Number Title Priority Date Filing Date
FI964593A FI118296B (fi) 1994-05-17 1996-11-15 Oraalisia nestemäisiä alendronaattikokoonpanoja

Country Status (33)

Country Link
US (1) US5462932A (fi)
EP (1) EP0759757B1 (fi)
JP (1) JP4111536B2 (fi)
KR (1) KR100372966B1 (fi)
CN (1) CN1079672C (fi)
AT (1) ATE222495T1 (fi)
AU (1) AU691634B2 (fi)
CA (1) CA2190148C (fi)
CO (1) CO4600739A1 (fi)
CY (1) CY2336B1 (fi)
CZ (1) CZ285860B6 (fi)
DE (1) DE69527842T2 (fi)
DK (1) DK0759757T3 (fi)
DZ (1) DZ1884A1 (fi)
ES (1) ES2180646T3 (fi)
FI (1) FI118296B (fi)
HR (1) HRP950293B1 (fi)
HU (1) HU220626B1 (fi)
IL (1) IL113651A (fi)
MX (1) MX9605660A (fi)
MY (1) MY112285A (fi)
NO (1) NO310179B1 (fi)
NZ (1) NZ289231A (fi)
PL (1) PL179634B1 (fi)
PT (1) PT759757E (fi)
RU (1) RU2176507C2 (fi)
SI (1) SI0759757T1 (fi)
SK (1) SK281098B6 (fi)
TW (1) TW402501B (fi)
UA (1) UA29505C2 (fi)
WO (1) WO1995031203A1 (fi)
YU (1) YU49354B (fi)
ZA (1) ZA953960B (fi)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780455A (en) * 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations
EA000347B1 (ru) * 1995-02-17 1999-04-29 Мерк Энд Ко., Инк. Способ уменьшения риска невертебральных переломов костей
JPH10506638A (ja) * 1995-05-12 1998-06-30 メルク エンド カンパニー インコーポレーテッド アレンドロネート又はその塩の投与による歯喪失の予防
IL118422A0 (en) * 1995-06-02 1996-09-12 Merck & Co Inc Use of alendronate for the prevention of osteoporosis
CA2221416A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. Bisphosphonate therapy for bone loss associated with rheumatoid arthritis
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
US6100301A (en) * 1996-02-28 2000-08-08 Pfizer Inc Combination therapy to treat osteoporosis-polyphosphonates and estrogen agonists
BR9712197A (pt) * 1996-10-04 1999-08-31 Merck & Co Inc Formulação farmacêutica líquida aquosa e processos de preparação da mesma, e, de inibição de reabsorção de osso.
US6376477B2 (en) 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
US6376476B1 (en) 1996-12-13 2002-04-23 Zymogenetics Corporation Isoprenoid pathway inhibitors for stimulating bone growth
US6080779A (en) * 1996-12-13 2000-06-27 Osteoscreen, Inc. Compositions and methods for stimulating bone growth
FI104901B (fi) 1997-10-20 2000-04-28 Leiras Oy Uudet metyleenibisfosfonihappojohdannaiset
GB9802617D0 (en) * 1998-02-07 1998-04-01 Knoll Ag Pharmaceutical formulation
US6331533B1 (en) 1998-11-16 2001-12-18 Merck & Co., Inc. Method for inhibiting dental resorptive lesions
US6194469B1 (en) * 1998-12-11 2001-02-27 Board Of Trustees Operating Michigan State Univeristy Method for inhibiting cyclooxygenase and inflammation using cherry bioflavonoids
HK1047399A1 (en) * 1999-06-02 2003-02-21 Sumitomo Pharmaceuticals Company, Limited Oral preparations of etidronate disodium
US6677320B2 (en) 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
US6468559B1 (en) 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
HUP0303700A3 (en) 2000-07-17 2006-07-28 Astellas Pharma Inc Chuo Ku Pharmaceutical composition improved in peroral absorbability
ES2243457T3 (es) * 2001-01-23 2005-12-01 Gador S.A. Composicion que comprende bifosfonatos para la prevencion y/o tratamiento de trastornos metabolicos de huesos, procedimiento de preparacion de dicha composicion y usos de la misma.
US8197561B2 (en) 2001-10-10 2012-06-12 River Basin Energy, Inc. Process for drying coal
US7537622B2 (en) * 2001-10-10 2009-05-26 Fmi Newcoal, Inc. Process for drying coal
US7695535B2 (en) 2001-10-10 2010-04-13 River Basin Energy, Inc. Process for in-situ passivation of partially-dried coal
JP2005516928A (ja) * 2001-12-13 2005-06-09 メルク　エンド　カムパニー　インコーポレーテッド 骨異常のためのビスホスホネート液体製剤
IL162053A0 (en) * 2001-12-21 2005-11-20 Procter & Gamble Method for the treatment of bone disorders
NZ556278A (en) * 2002-05-10 2009-06-26 Hoffmann La Roche Bisphosphonic acid for the treatment and prevention of osteoperosis
ITTO20020406A1 (it) * 2002-05-13 2003-11-13 Chiesi Farma Spa Formulazioni di bisfosfonati ad uso iniettabile.
US7041309B2 (en) * 2002-06-13 2006-05-09 Neuropro Technologies, Inc. Spinal fusion using an HMG-CoA reductase inhibitor
GR1004331B (el) * 2002-10-07 2003-09-05 Verisfield (Uk) Ltd Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας αλενδρονικου οξεος
ES2530791T3 (es) * 2002-12-20 2015-03-05 Hoffmann La Roche Formulación de ibandronato de altas dosis
US20050101605A1 (en) * 2003-11-07 2005-05-12 Ahmed Salah U. Oral liquid formulations of methotrexate
DK1753395T3 (da) * 2004-05-24 2010-11-08 Warner Chilcott Co Llc Enterisk, fast, oral doseringsform af et bisphosphonat, der indeholder et chelateringsmiddel
US7645460B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US20080287400A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US20080286359A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645459B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
CN1997374A (zh) * 2004-06-23 2007-07-11 默克公司 雌激素受体调节剂
AU2005275193A1 (en) * 2004-07-15 2006-02-23 Nanobac Life Sciences Methods and compositions for the administration of calcium chelators, bisphosphonates and/or citrate compounds and their pharmaceutical uses
WO2006020009A1 (en) * 2004-07-23 2006-02-23 The Procter & Gamble Company Solid oral dosage form of a bisphosphonate containing a chelating agent
WO2008128056A1 (en) * 2004-10-08 2008-10-23 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps
EP1802641B8 (en) * 2004-10-08 2012-03-07 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US20060134190A1 (en) * 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
WO2007095161A2 (en) * 2006-02-14 2007-08-23 New York University Methods and compositions for treating disorders associated with increased bone turnover and osteopenia
AU2007226964B2 (en) * 2006-03-17 2012-03-22 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
DK1894557T3 (da) * 2006-09-04 2011-05-30 Gador Sa Flydende sammensætning til behandling og/eller forebyggelse af forskellige metaboliske knoglesygdomme, anvendelse heraf og fremgangsmåde til fremstilling heraf
CA2658834A1 (en) * 2006-11-21 2008-05-29 Teikoku Pharma Usa, Inc. Bisphosphonate inhalant formulations and methods for using the same
US8974801B2 (en) * 2006-12-21 2015-03-10 Amphastar Pharmaceuticals Inc. Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
US20090170815A1 (en) * 2007-12-28 2009-07-02 Roxane Laboratories Incorporated. Alendronate oral liquid formulations
CA2711413A1 (en) * 2008-02-05 2009-08-13 Actavis Group Ptc Ehf Alendronate formulations, method of making and method of use thereof
US20100034752A1 (en) * 2008-08-11 2010-02-11 Toru Hibi Inhalant formulations comprising a bisphosphonate and a pyrazolone derivative and methods for using the same
US9057037B2 (en) 2010-04-20 2015-06-16 River Basin Energy, Inc. Post torrefaction biomass pelletization
US8956426B2 (en) 2010-04-20 2015-02-17 River Basin Energy, Inc. Method of drying biomass
US9889225B2 (en) * 2010-08-20 2018-02-13 Kaohsiung Medical University Method for bone formation by administering poly(lactic-co-glycolic acid) cross-linked alendronate
PL2648702T3 (pl) 2010-12-06 2019-07-31 Effrx Pharmaceuticals Sa Stabilne musujące formulacje bisfosfonianowe z cechą szybkiej solubilizacji
CN103070824B (zh) * 2013-01-24 2014-07-16 天津红日药业股份有限公司 一种含有伊班膦酸钠的注射液
EP3054980B1 (en) * 2013-10-08 2019-09-04 InnoPharma, Inc. Aprepitant oral liquid formulations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1187828B (it) * 1985-05-24 1987-12-23 Gentili Ist Spa Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi
GB8618259D0 (en) * 1986-07-25 1986-09-03 Leo Pharm Prod Ltd Pharmaceutical compositions
DE3822650A1 (de) * 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
FI83421C (fi) * 1989-06-21 1991-07-10 Huhtamaeki Oy Foerfarande foer framstaellning av farmakologiskt anvaendbara metylenbisfosfonsyraderivat.
US5227506A (en) * 1989-09-06 1993-07-13 Merck & Co., Inc. Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors
CA2035179C (en) * 1990-01-31 2001-08-14 Gerald S. Brenner Pharmaceutical compositions containing insoluble salts of bisphosphonic acids
US5356887A (en) * 1990-01-31 1994-10-18 Merck & Co., Inc. Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
RU2029550C1 (ru) * 1992-03-20 1995-02-27 Светлана Семеновна Родионова Способ коррекции метаболизма костной ткани
FR2703590B1 (fr) * 1993-04-05 1995-06-30 Sanofi Elf Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse .

Also Published As

Publication number Publication date
JP4111536B2 (ja) 2008-07-02
HRP950293A2 (en) 1997-04-30
IL113651A (en) 1999-08-17
DZ1884A1 (fr) 2002-02-17
JPH10504020A (ja) 1998-04-14
ATE222495T1 (de) 2002-09-15
HU220626B1 (hu) 2002-03-28
ES2180646T3 (es) 2003-02-16
DE69527842D1 (de) 2002-09-26
CA2190148A1 (en) 1995-11-23
HUT76317A (en) 1997-08-28
YU49354B (sh) 2005-09-19
US5462932A (en) 1995-10-31
HU9603162D0 (en) 1997-01-28
CO4600739A1 (es) 1998-05-08
TW402501B (en) 2000-08-21
UA29505C2 (uk) 2000-11-15
CN1079672C (zh) 2002-02-27
KR970703151A (ko) 1997-07-03
WO1995031203A1 (en) 1995-11-23
NO964864L (no) 1996-11-15
EP0759757A1 (en) 1997-03-05
HK1009245A1 (en) 1999-05-28
IL113651A0 (en) 1995-08-31
EP0759757B1 (en) 2002-08-21
SK281098B6 (sk) 2000-11-07
CZ336796A3 (en) 1997-06-11
MY112285A (en) 2001-05-31
SK147796A3 (en) 1997-07-09
YU31795A (sh) 1999-06-15
NO310179B1 (no) 2001-06-05
CY2336B1 (en) 2004-02-06
DK0759757T3 (da) 2002-10-07
PL179634B1 (pl) 2000-10-31
AU2901095A (en) 1995-12-05
HRP950293B1 (en) 2003-08-31
CA2190148C (en) 2006-02-14
FI964593A0 (fi) 1996-11-15
CN1148341A (zh) 1997-04-23
KR100372966B1 (ko) 2003-05-12
MX9605660A (es) 1998-02-28
SI0759757T1 (en) 2002-12-31
DE69527842T2 (de) 2003-04-10
ZA953960B (en) 1996-01-19
PL320614A1 (en) 1997-10-13
RU2176507C2 (ru) 2001-12-10
NO964864D0 (no) 1996-11-15
NZ289231A (en) 1998-04-27
CZ285860B6 (cs) 1999-11-17
AU691634B2 (en) 1998-05-21
FI118296B (fi) 2007-09-28
PT759757E (pt) 2002-11-29

Similar Documents

Publication Publication Date Title
FI964593L (fi) Oraalisia nestemäisiä alendronaattikokoonpanoja
DK1093815T3 (da) Oral 2-methyl-thieno-benzodiazepinformulering
DK0853945T3 (da) Flydende gonadotropinholdige formuleringer
FI963421A7 (fi) Oraalisia apuainekoostumuksia
DE69512647D1 (de) Durchsichtiges flüssiges zahnputzmittel
BR9610153A (pt) Formulações farmacêuticas
BR9611626A (pt) Formulações farmacéuticas
FI20071025L (fi) Farmaseuttisia koostumuksia
NO954486D0 (no) Farmasöytiske formuleringsgrunnlag
FI970603L (fi) Nestemäisiä immunoglobuliiniformulaatioita
BR9508844A (pt) Composição oral
BR9506536A (pt) Composição oral
FI950402A7 (fi) Oraaliset koostumukset
FI954243A7 (fi) Farmaseuttiset yhdisteet
FI951316L (fi) Peroraalinen formulaatio
BR9510467A (pt) Composições orais
DE69421621D1 (de) Verbesserte zahnfadenspenderphiole
BR9510307A (pt) Composições orais
DE69411573D1 (de) Feste Glyphosat-Formulierungen
DE69521906D1 (de) Zahnhygiene - präparate
EE9900113A (et) Vedelad alendronaatpreparaadid
ITMI941169A0 (it) Formulazioni farmaceutiche
EP0837863A4 (en) DISODIUM ALENDRONATE PREPARATIONS
ITMI942166A0 (it) Composizioni farmaceutiche miorilassanti
ATA194094A (de) Artikulator

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 118296

Country of ref document: FI

PC Transfer of assignment of patent

Owner name: MERCK SHARP & DOHME CORP.

Free format text: MERCK SHARP & DOHME CORP.

PC Transfer of assignment of patent

Owner name: MERCK SHARP & DOHME CORP.

MA Patent expired